Vizient, Inc. announced that pharmacy expert Katrina Harper, PharmD, MBA, BCPS, clinical pharmacy director, will present at the Healthcare Distribution Alliance’s 2020 Traceability Online Seminar. The event, which is being held virtually Nov. 2-4, brings together stakeholders from the health care supply chain to learn more about upcoming DSCSA implementation milestones for serialization and traceability technologies to further preserve the safety and security of pharmaceuticals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201103005087/en/
Katrina Harper, PharmD, MBA, BCPS, clinical pharmacy director, Vizient, will present at the Healthcare Distribution Alliance’s 2020 Traceability Online Seminar. (Photo: Business Wire)
Harper will participate in the panel discussion “Perspectives from the Dispenser Community” on Tuesday, Nov. 3 from 2:30-3:30 p.m. EST. Panelists will share their current thinking, approaches and challenges regarding the implementation of DSCSA. Topics to be addressed will include the structure of, and planning toward, a 2023 system; cost concerns; scanning and hardware upgrades across the dispensing community; communication strategies regarding packaging and bar code changes; and how dispensers report issues to FDA and upstream to suppliers.
“As with most regulatory requirements put into place to improve our health care system, there are milestones along the way that must be met,” said Harper. “Some of the requirements have already gone into effect, yet many in the industry are unaware or unprepared for what is already in play and what is yet to come. This discussion will help those impacted to better understand the requirements and what they will need to plan for in order to be ready.”
About Vizient, Inc.
Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nation’s acute care providers, which includes 95% of the nation’s academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a World’s Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005087/en/
ALBUQUERQUE, N.M. (AP) — It could be well into next year before a COVID-19 vaccine is widely available, but top health officials in New Mexico said Tuesday that they have submitted their plan to the federal government for building the infrastructure, tracking systems and partnerships that will be needed for distribution.
The focus will be on vaccinating health care workers and first responders, then nursing home residents and staff. They acknowledged that supplies will likely be limited early on and immunizations for the general public would come later.… Read More
“CBS This Morning” explores whether America is ready for avaccine in a special three-part series, Road to a Vaccine. Part three airs Wednesday, October 28 on “CBS This Morning,” 7-9 a.m. on CBS. Watch part one .
The earliest a coronavirus vaccine is expected to be ready for FDA authorization is the. The CDC has already given states $200 million to prepare for distribution.
But shipping companies like DHL have a daunting task — preparing to transport a coronavirus vaccine without knowing where the vaccine will be manufactured, what the packaging will be or how cold it will need to be kept.
“There’s still a lot of things that are unknown. And we’ve been talking to the different manufacturers, who are in various phases of the clinical trials to get ready,” DHL’s CEO of Global Forwarding USA David Goldberg told CBS News senior medical correspondent Dr. Tara Narula.
At the DHL cold-chain facility near Chicago’s O’Hare airport, vaccines are stored at various temperatures before they’re sent to doctors’ offices, pharmacies and hospitals.
“We’ve been moving the flu vaccine, the meningitis vaccine,” Goldberg said. “I think the challenge related to this vaccine is it’s, you know, a vaccine that the world needs as soon as possible, at once, which will make it very difficult in terms of logistics.”
The colder the vaccine, the more complicated the logistics.needs to be kept at about minus 94 degrees Fahrenheit, while needs to be stored at minus 4 degrees Fahrenheit.
“A lot of providers don’t have that type of storage,” said North Dakota Immunization Program Manager Molly Howell.
The ultra-cold storage requirement will make it challenging for states to get the vaccine to their residents, Howell said.
“Once a provider receives that vaccine, it really starts the clock that the vaccine needs to be administered within five days of when it’s put in the refrigerator,” she said.
Pfizer’s vaccine is expected to ship in containers with almost 1,000 shots, which worries Howell.
“The minimum increment of 1,000 doses and figuring out how we can get that to the rural areas is what’s keeping me up at night,” she said. “We’re thinking about the possibility of having to repackage and redistribute that vaccine into smaller quantities.”
While states like North Dakota gear up for mass distribution, the pandemic continues to batter state budgets. The trade associations that represent health officials across the country have asked Congress for $8.4 billion to help states distribute the vaccine.
States and their health departments are “tapped out financially,” said Georgetown professor Dr. Jesse Goodman.
“Also, in terms of their human resources, they’ve been running at 100 miles an hour to do the contact tracing to make up for a not very efficient federal response,” he said.
Goodman said there needs to be an effective national system for distributing and monitoring the vaccine.
“Otherwise, it’s going to be chaos,” Goodman said. “We may have multiple vaccines. We may
AUSTIN, TX — Austin Public Health officials on Friday launched a so-called Vaccine Distribution Coalition in preparing for availability of a vaccine for the coronavirus one it’s readily available.
The coalition comprises local health care and community partners with an aim to assist the health district in developing strategies for vaccination coverage, Austin Public Health officials wrote in an advisory. Coalitions within local jurisdictions were identified by the federal government as a best practice and are key to successful rapid vaccine distribution planning, officials added.
“Slowing the spread of COVID-19 in Austin-Travis County has been a community effort since the beginning,” Austin Public Health Director Stephanie Hayden said in a prepared statement. “Planning for the distribution of a COVID-19 vaccine will once again require many stakeholders and a community effort to be successful. We still have a long road ahead of us, but the COVID-19 Vaccine Distribution Coalition marks the beginning of a new chapter in our response.”
Local officials have been guided by a Centers for Disease Control and Prevention publication titled the COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations, which includes information on vaccination program planning and implementation tactics, Austin Public Health officials said. COVID-19 vaccine supply is expected to be limited at the beginning of distribution, local officials noted, so the allocation of doses may need to be prioritized for critical populations such as critical infrastructure workers, people at increased risk for severe COVID-19 illness, people at increased risk of acquiring or transmitting COVID-19, and people with limited access to routine vaccination services.
“As a community, we need to recognize that even when a vaccine becomes available, initially it will not be widely available for the general public,” Dr. Mark Escott, the interim Austin-Travis County health authority, said in a prepared statement. “We will need to prioritize our most vulnerable and ensure equitable distribution across our community.”
Austin Public Health officials said initial coalition meetings will focus on identifying these critical populations as well as strategizing for distribution channels, vaccine temperature storage and management along with community messaging and engagement efforts.
For COVID-19 information and updates, visit the COVID-19 Information page in the City of Austin website.
This article originally appeared on the Austin Patch
The global sports nutrition market size is poised to grow by USD 8.74 billion during 2020-2024, progressing at a CAGR of almost 8% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005149/en/
Technavio has announced its latest market research report titled Global Sports Nutrition Market 2020-2024 (Graphic: Business Wire)
The sports nutrition market is driven by the expansion of distribution channels. The increase in demand for sports nutrition products has expanded their distribution channels. These products are one of the largest and fastest-growing categories in both retail and online channels. Products are distributed through numerous retail channels, such as large retail and mass merchandisers, supermarkets, hypermarkets, small retail stores, drug and specialty stores, fitness institutions, and various online retailers. Marketing strategies of various retail stores, which are stressing toward pushing quality ingredients and certifications including ELISA testing, gluten-free, or third-party banned substance testing certificates, are fueling the sales of sports supplements in the global market. The online distribution channels of the global sports nutrition market are expected to grow at a rapid pace, and the market will grow swiftly during the forecast period.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
The major sports nutrition market growth came from the non-protein sports nutrition segment in 2019, and is expected to register the highest growth during the forecast period.
North America was the largest sports nutrition market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. This is attributed to factors such as the growing demand for sports nutrition products, inclination toward healthy eating and RTD, the growing number of health clubs, and the rising demand for meal-replacement powders.
The global sports nutrition market is fragmented. Abbott Laboratories, Clif Bar & Co., Glanbia Plc, Klean Athlete, Momentous, MusclePharm Corp., NOW Health Group Inc., PepsiCo Inc., Pro Action srl, and Weider Global Nutrition. are some of the major market participants. To help clients improve their market position, this sports nutrition market forecast report provides a detailed analysis of the market leaders.
As the business impact of COVID-19 spreads, the global sports nutrition market 2020-2024 is expected to have positive growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Increasing use of innovative ingredients will be a Key Market Trend
The increasing use of innovative ingredients is identified as
Clostridium Vaccine Market Research Report by Animal Type, by Distribution Channel – Global Forecast to 2025
Clostridium Vaccine Market Research Report by Animal Type (Bovine, Ovine, Poultry, and Swine), by Distribution Channel (Hospitals, Veterinary Clinics, and Veterinary Research Institute) – Global Forecast to 2025 – Cumulative Impact of COVID-19
New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Clostridium Vaccine Market Research Report by Animal Type, by Distribution Channel – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913851/?utm_source=GNW
The Global Clostridium Vaccine Market is expected to grow from USD 416.46 Million in 2019 to USD 591.30 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.01%.
Market Segmentation & Coverage:
This research report categorizes the Clostridium Vaccine to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Animal Type, the Clostridium Vaccine Market studied across Bovine, Ovine, Poultry, and Swine.
Based on Distribution Channel, the Clostridium Vaccine Market studied across Hospitals, Veterinary Clinics, and Veterinary Research Institute.
Based on Geography, the Clostridium Vaccine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Clostridium Vaccine Market including ARKO laboratories, Bayer AG, Bimeda, Inc., Boehringer Ingelheim, Ceva logistics, Colorado Serum Company, Merck & Co. Inc., Nuovo Biologics, LLC, Virbac, and Zoetis Services LLC.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clostridium Vaccine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant
In Kalamazoo, Mich., a stretch of land the size of a football field has been turned into a staging ground outfitted with 350 large freezers, ready to take delivery of millions of doses of Covid-19 vaccine before they can be shipped around the world.
The facility is a hub in the sprawling supply chain
has built to handle the delivery of a vaccine widely awaited as a possible relief from the coronavirus pandemic. The U.S. pharmaceutical giant says it wants to deliver up to 100 million doses this year and another 1.3 billion in 2021.
Like other drugmakers testing potential vaccines, Pfizer is urgently laying the groundwork with its logistics partners so it can move quickly if its vaccine gets the go-ahead from the Food and Drug Administration and other regulators around the world.
“It’s the biggest-ever vaccination campaign,” said Tanya Alcorn, Pfizer’s supply-chain vice president. “If we get the FDA approval, we will be able to ship the vaccines very shortly after.”
The New York-based drugmaker is working with Germany’s
on one of several experimental Covid-19 vaccines in late-stage testing. Pfizer says it may know whether its vaccine works by the end of October and that it could be ready to apply for emergency-use authorization of its Covid-19 vaccine by late November.
The company’s effort to deliver relief to pandemic-weary populations will revolve around refrigerated storage sites at two of the company’s final assembly centers—the Kalamazoo facility and another in Puurs, Belgium—and rely on dozens of cargo-jet flights and hundreds of truck trips every day. Distribution centers in Pleasant Prairie, Wis., and in Karlsruhe, Germany, have been outfitted for extra storage capacity.
Pfizer so far has spent about $2 billion on developing the vaccine and setting up the distribution network.
The U.S. government placed an initial order for 100 million doses, with the option to purchase 500 million additional doses. The EU ordered 200 million doses with an option for another 100 million. Japan ordered 120 million doses and the U.K. 30 million. Countries in South America and in the Asia-Pacific region also have placed significant orders.
In a typical vaccination campaign, pharmaceutical companies would wait until their product is approved before buying raw materials, establishing manufacturing lines and setting up supply chains to ship a vaccine.
Pfizer Chief Executive Albert Bourla said that the company began setting the groundwork for its supply chain in March, when it kicked off its vaccine development.
“Ensuring over a billion people globally have access to our potential vaccine is as critical as developing the vaccine itself,” he said.
Pfizer says it is preparing for distribution in case the vaccine wins authorization, with hundreds of thousands of doses already in the company’s warehouses in the U.S. and Europe.
Cool Box To make sure its Covid-19 vaccine doses arrive at hospitals and clinics frozen and potent, Pfizer created
Massachusetts Governor Charlie Baker said Tuesday the state is developing a plan to distribute a COVID-19 vaccine. The plan lays out the initial steps for a “robust, comprehensive and equitable” vaccine distribution system once one or more vaccines become available.
Officials anticipate limited supply in the early phase and plan to prioritize some health care workers, people at increased risk of severe illness from COVID-19 – including people with underlying medical conditions and those older than 65 – and other essential workers, Baker said.
“The plan also outlines our messaging efforts to make sure people know once there is a vaccine available, that it has been approved by the federal government and is safe and effective,” he said.
“We’ll also make it a priority to reach out specifically to groups that have been disproportionately impacted by COVID-19, including people and communities of color.”
Baker called it an interim plan “that will probably change as more information becomes available.”
Massachusetts is among the states that has recently seen an uptick in COVID-19 cases. As of mid-last week, a total of 63 communities in the state, including Boston, were considered high risk for virus infections, up from 40 a week before. The designation is based on average daily cases per 100,000 residents, CBS Boston reported. High risk communities are those with over 8 cases per 100,000 residents during the last 14 days.
“While we continue to plan for distribution of a vaccine, we can’t take our eyes off the measures that we’ve been talking about for the last several months to keep people safe,” Baker said Tuesday.
late last week that officials are now giving “special attention” to gatherings and house parties “that are putting other people at risk,” as the city sees a rise in coronavirus cases.
“We are tracing locations where house parties continue to happen,” Walsh said, adding they are working with Boston’s Inspectional Services department “to curtail these events.”
Roughly half of new cases in the city continue to be in people who are under 30, said Walsh, who advised people to “get on Zoom” and socialize digitally.
Pressure to create a coronavirus vaccine is increasing by the day, but for a safe vaccine to enter the market, it takes time.
State public health departments say they’re ready to leap into action as soon as a COVID-19 vaccine is approved but caution so many things are still unknown that exactly what that leap looks like is hard to say right now.
For Dr. Nirav Shah, director of the Maine Center for Disease Control and Prevention, it’s like planning an outdoor picnic for 1.3 million of his closest friends (the population of Maine) without knowing how much food he has, who’s coming, how he’s going to invite them and what they can and can’t eat.
“We plan for things we have knowledge around and move forward from there,” he said.
The good news is that the earliest date a vaccine is expected to arrive is now around Thanksgiving so that gives states a little breathing room. There had been the possibility that a vaccine could become available as soon as Nov. 1.
To get ready, in Maine the public health department is planning “down to the person,” Shah said. “We’re looking at how many miles our public health nurses may need to drive.”
On Friday state public health departments submitted vaccination distribution plans to the U.S. Centers for Disease Control. The plans were as detailed as they could be given the many things that are still unknown:
- When a vaccine or vaccines will become available.
- Which groups will be first in line to get it and who comes next.
- What kind of storage and refrigerator or freezer requirements they might have. At least one must be stored at -94°.
- For vaccines that require two doses (all but one), when the second dose must be administered.
- Information about whether a certain vaccine works or doesn’t work in specific populations such as the elderly, pregnant women or the young.
In a call with reporters Monday, public health officials talked about how they’re preparing and what they still need.
This involves hours and hours of meetings: Last week state health officials spent two hours meeting with Pfizer just about the packaging it has developed to keep the vaccine cold as it’s distributed and stored, said Claire Hannan, executive director of the Association of Immunization Managers.
Latest news: Global COVID cases pass 40M; US nears 220K deaths; Fauci not surprised Trump was infected
Deadly discrimination: Asian Americans in San Francisco are dying at alarming rates from COVID-19: Racism is to blame
Maine’s Shah said he’s having multiple meetings every day and many at night to get ready for what will be one of the biggest public health pushes of the modern era.
The final plan for who gets COVID-19 vaccine first will come from the CDC’s Advisory Committee on Immunization Practices. That committee is standing ready to meet the day or the day after a vaccine is approved, Shah said.
Where will your family be? Expert panel recommends who should